Search Results - "Joseph‐Ridge, N."

Febuxostat (TMX-67), a Novel, Non-Purine, Selective Inhibitor of Xanthine Oxidase, Is Safe and Decreases Serum Urate in Healthy Volunteers by Becker, M. A., Kisicki, J., Khosravan, R., Wu, J., Mulford, D., Hunt, B., MacDonald, P., Joseph-Ridge, N.

“…In order to evaluate the safety, pharmacological properties, and urate-lowering efficacy of febuxostat, a non-purine, selective inhibitor of xanthine oxidase,…”
Get full text

Magnetic resonance imaging in the quantitative assessment of gouty tophi by Schumacher, Jr, H R, Becker, M A, Edwards, N L, Palmer, W E, MacDonald, P A, Palo, W, Joseph-Ridge, N

“…Measurements of tophus size can be important in monitoring the course of gout therapy, as tophus resolution is proposed as one measure of success of treatment…”
Get more information

Gout Assessment Questionnaire: Initial results of reliability, validity and responsiveness by Colwell, H H, Hunt, B J, Pasta, D J, Palo, W A, Mathias, S D, Joseph-Ridge, N

“…We evaluated the psychometric properties of a new gout-specific patient reported outcomes questionnaire. The Gout Assessment Questionnaire (GAQ) and the SF-36…”
Get more information

Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout by Becker, Michael A, Schumacher, H. Ralph, Wortmann, Robert L, MacDonald, Patricia A, Eustace, Denise, Palo, William A, Streit, Janet, Joseph-Ridge, Nancy

“…In this randomized trial of patients with elevated uric acid levels and gout, febuxostat, a new nonpurine selective inhibitor of xanthine oxidase, was compared…”
Get full text

Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population by WALLACE, Katrine L, RIEDEL, Aylin A, JOSEPH-RIDGE, Nancy, WORTMANN, Robert

“…OBJECTIVE: To determine whether the prevalence of gout and/or clinically significant hyperuricemia increased in a managed care population over 10 years…”
Get full text

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28‐week, phase III, randomized, double‐blind, parallel‐group trial by Schumacher, H. RALPH, Becker, Michael A., Wortmann, Robert L., MacDonald, Patricia A., Hunt, Barbara, Streit, Janet, Lademacher, Christopher, Joseph‐Ridge, Nancy

“…Objective To compare the urate‐lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout,…”
Get full text

Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims by RIEDEL, Aylin A, NELSON, Michael, JOSEPH-RIDGE, Nancy, WALLACE, Katrine, MACDONALD, Patricia, BECKER, Michael

“…OBJECTIVE: Poor compliance with gout medications has been recognized, but seldom studied. We investigated compliance with allopurinol among managed care…”
Get full text

Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment by Mayer, Michael D, Khosravan, Reza, Vernillet, Laurent, Wu, Jing-Tao, Joseph-Ridge, Nancy, Mulford, Darcy J

“…To assess the safety, pharmacokinetics, and pharmacodynamics of febuxostat in subjects with normal renal function or renal impairment, febuxostat (80 mg/d) was…”
Get full text

The Effect of Mild and Moderate Hepatic Impairment on Pharmacokinetics, Pharmacodynamics, and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase by Khosravan, Reza, Grabowski, Brian A., Mayer, Michael D., Wu, Jing-Tao, Joseph-Ridge, Nancy, Vernillet, Laurent

“…To assess the effect of hepatic impairment on the pharmacokinetics, pharmacodynamics, and safety of febuxostat at steady state, multiple once‐daily 80‐mg oral…”
Get full text

Outcome measures for acute and chronic gout by H Ralph Schumacher, Jr, Lawrence N Edwards, Fernando Perez-Ruiz, Michael Becker, Lan X Chen, Daniel E Furst, Nancy Joseph-Ridge, Naomi Schlesinger, Zeb Horowitz, Kenneth Saag, Judith A Boice, Hisashi Yamanaka, OMERACT 7 Special Interest Group

“…Gout provides some unique challenges in classification and measurement of outcomes. Our aim was to evaluate criteria for classification and to develop and…”
Get full text

PI-55 by Khosravan, R., Wu, J., Joseph‐Ridge, N., Vernillet, L.

“…AIMS The objective of this study was to evaluate the population (pop) PK and PD of febuxostat (FBX), a non‐purine selective inhibitor of xanthine oxidase, in…”
Get full text

Tophaceous gout: quantitative evaluation by direct physical measurement by H Ralph Schumacher, Jr, Michael A Becker, William A Palo, Janet Streit, Patricia A MacDonald, Nancy Joseph-Ridge

“…OBJECTIVE: The absence of accepted standardized methods for monitoring tophaceous gout limits the ability to track tophus progression or regression. This…”
Get full text

Prevalence of Comorbid Conditions and Prescription Medication Use Among Patients With Gout and Hyperuricemia in a Managed Care Setting by Riedel, Aylin Altan, Nelson, Mike, Wallace, Katrine, Joseph-Ridge, Nancy, Cleary, Michele, Fam, Adel G

“…BACKGROUND:Comorbid disorders and multiple prescription drug use are common among patients with gout and/or hyperuricemia and may influence the clinical course…”
Get full text

REDUCTION IN GOUT FLARES AND TOPHUS SIZE IN THE 52-WEEK FEBUXOSTAT ALLOPURINOL CONTROLLED TRIAL (FACT): 28 by Schumacher, Ralph H., MacDonald, P, Lloyd, E, Joseph-Ridge, N

Get full text

Effect of food or antacid on febuxostat pharmacokinetics and pharmacodynamics in healthy subjects by Khosravan, R., Grabowski, B., Wu, J. T., Joseph‐Ridge, N., Vernillet, L.

“…Febuxostat is a novel non‐purine selective inhibitor of xanthine oxidase (NP‐SIXO) being developed for the management of hyperuricemia in patients with gout…”
Get full text

Effects of age and gender on febuxostat pharmacokinetics, pharmacodynamics, and safety in healthy subjects by Khosravan, R., Kukulka, M., Wu, J. T., Joseph‐Ridge, N., Vernillet, L.

“…Background Febuxostat is a novel non‐purine selective inhibitor of xanthine oxidase (NP‐SIXO) being developed for the management of hyperuricemia in patients…”
Get full text

Effect of febuxostat on pharmacokinetics of desipramine, a CYP2D6 substrate, in healthy subjects by Khosravan, R., Erdman, K., Vernillet, L., Wu, J. T., Joseph‐Ridge, N., Umeda, S., Mulford, D.

“…Febuxostat is a novel non‐purine selective inhibitor of xanthine oxidase (NP‐SIXO) being developed for the management of hyperuricemia in patients with gout…”
Get full text

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty‐eight–day, multicenter, phase II, randomized, double‐blind, placebo‐controlled, dose‐response clinical trial examining safety and efficacy in patients with gout by Becker, Michael A., Schumacher, H. Ralph, Wortmann, Robert L., MacDonald, Patricia A., Palo, William A., Eustace, Denise, Vernillet, Laurent, Joseph‐Ridge, Nancy

“…Objective Gout affects ∼1–2% of the American population. Current options for treating hyperuricemia in chronic gout are limited. The purpose of this study was…”
Get full text